

MEMORANDUM TO SENATOR DOLE

DA: May 12, 1995
FR: Alec Vachon
RE: UPDATE/MEETING WITH ARTHUR ULLIAN

As I have written you, I met w/Ullian last week to explore how biomedical research might help contain health and long-term care costs. He brought 6 experts w/him--list attached.

Apart from whether or not biomedical research can offer cost savings in the near future, it is an issue of HOPE for many people with a disability or chronic disease (e.g., arthritis)--and projects compassion. A possible campaign issue.

OTHER SENATORS ARE SKEPTICAL. Ullian has been shopping this project among members for 2 years--including Hatfield, Harkin, Stevens, Rockefeller, etc. Although some have shown interest, bottomline most seem to feel that significant cost savings from biomedical research is "pie in the sky." Ullian recently attended a fundraiser for Cohen, and may be a witness before the Aging Committee on this issue.

As a scientist by training myself, I have always found it mysterious that as a nation we don't invest more in biomedical science. Disease and disability are matters of damaged tissue--and although new ways to fix damaged tissue won't be simple to find, every problem can be solved eventually.

NEXT STEP WITH ULLIAN. I left it w/Ullian that we needed to give this issue credibility--perhaps with some specific examples of how costs savings might be achieved through achievable, near-term medical breakthroughs. Specifically, given approx. \$260 billion in Medicare costs in 2000, what breakthroughs could make a dent in this number?

I am cautious in making a specific recommendation to you at this time regarding a task force with Ullian as head until we have more information. Also, Ullian is like a fire hose--puts out lots of pressure and needs control.

UNHAPPY PHONE CALL. I received a phone call from a Larry Hoffheimer (who lobbies for a number of patient groups), and claims to advise Mike Bromberg on medical research for the campaign. Larry apparently had heard a rumors about this meeting--and seemed a little incensed that a "big Democrat" like Ullian was in. More to the point, he felt this issue is incredibly important--for reasons of hope and compassion--and is almost wholly neglected.

- Dan
- Arthur

To: Dr. Alexander Vachon, Office of Senator Dole
From: Arthur D. Ullian, Chairman, END
Re: Task Force Meeting Attendees -- Monday, May 1, 2:30 PM

Paul Calabresi, M.D., M.A.C.P.
Professor of Medicine & Chairman Emeritus
Brown University Dept. of Medicine
Chair, National Cancer Advisory Board (Bush appointment)

Robert Goldberg, Ph.D.
Health Care Policy Analyst
Gordon Public Policy Center, Brandeis University
Center for Neuroscience, Behavior & Society, G.W. University

Guy McKhann, M.D.
Professor of Neurology and Director,
Krieger Mind/Brain Institute, Johns Hopkins University
Exec. Committee, The Dana Alliance for Brain Initiatives

Frederick Goodwin, MD
Professor of Psychiatry & Neuroscience
George Washington University Medical School
Former Director, NIMH

Marianne McGettigan, J.D., M.P.A.
Law offices of Verrill & Dana, Portland, ME
Special Advisor to President Bush for Policy Development

John Clarke
Principal, DSV Partners, (Venture Capital Co. to the Biotech.
firms) Princeton, NJ
Founder, Alkermes, Inc.

Leslie R. Kenney
Public Education, END

Arthur D. Ullian
Chairman, END